Challenges in Disproportionality Analysis: Understanding Their Intricate Nature and Proposing an Initial Mitigation Approach
By
Manfred Hauben
Rave Harpaz
Robert Weber
September 17, 2026
Clinical Scorecard: Challenges in Disproportionality Analysis: Understanding Their Intricate Nature and Proposing an Initial Mitigation Approach
At a Glance
Category Detail
Condition Disproportionality Analysis (DPA) Key Mechanisms Regression-adjusted gamma-Poisson shrinker (RGPS) for mitigating confounding and masking in drug-event associations. Target Population Nonspecialist pharmacovigilance analysts evaluating drug safety signals. Care Setting Pharmacovigilance and drug safety monitoring.
Key Highlights
RGPS combines logistic regression with DPA's observed-to-expected framework. Masking can conceal true drug-event associations, which RGPS aims to unmask. Confounding by demographic variables can distort drug-event association signals. Standardized regression coefficients (SRCs) help identify sources of masking and confounding. Likelihood ratio (LLR) statistics assess model fit improvements. Guideline-Based Recommendations
Diagnosis
Utilize RGPS to adjust for confounding factors in DPA. Management
Incorporate regression models to refine drug-event association assessments. Monitoring & Follow-up
Regularly evaluate the impact of co-reported drugs on adverse event reporting. Risks
Be aware of potential masking and confounding that may lead to misinterpretation of DPA results. Patient & Prescribing Data
Patients exposed to drugs under evaluation for adverse events.
Consider the role of co-medications and demographic factors in adverse event reporting.
Clinical Best Practices
Employ regression-adjusted methods for more accurate DPA outcomes. Account for demographic variables in analyses to avoid confounding. Monitor for masking effects in drug-event associations. Related Resources & Content
